Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
EurekAlert!1d
Study shows promise for treating core symptom of frontotemporal dementia
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
FiercePharma11d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla ... the active ingredient in Ozempic and Wegovy, in Alzheimer’s is built on a series of studies that have linked GLP-1 analogs ...
Verywell Health on MSN4d
What's New in Alzheimer's Treatment?
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Business Insider5d
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report ... forthcoming Phase 3 clinical trials for Orfoglipron.
biznews.com7d
🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows
A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.
FiercePharma7d
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...